报价延迟最少15分钟:2026/04/15 13:33 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.2 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.42/0.36
|
|
企业价值
980.68M
|
| 资产负债 |
|
每股账面净值
-0.07
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
81.39M
|
|
每股收益
0.08
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union. |
